Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1961 1
1962 1
1963 2
1964 2
1965 1
1966 1
1968 3
1969 1
1972 2
1973 1
1974 2
1975 2
1976 1
1977 4
1978 4
1979 1
1980 5
1981 2
1982 7
1983 13
1984 10
1985 12
1986 16
1987 16
1988 14
1989 12
1990 20
1991 27
1992 24
1993 24
1994 21
1995 38
1996 30
1997 36
1998 37
1999 44
2000 40
2001 66
2002 75
2003 133
2004 184
2005 200
2006 233
2007 269
2008 282
2009 311
2010 387
2011 482
2012 553
2013 666
2014 797
2015 909
2016 995
2017 1090
2018 1280
2019 1382
2020 1675
2021 1966
2022 2360
2023 2531
2024 2973
2025 1292

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21,126 results

Results by year

Filters applied: . Clear all
Page 1
Targeting GOLPH3L improves glioblastoma radiotherapy by regulating STING-NLRP3-mediated tumor immune microenvironment reprogramming.
Sun S, Qian S, Wang R, Zhao M, Li R, Gu W, Zhao M, Qian C, Liu L, Tang X, Li Y, Shi H, Pan Y, Xiao H, Yang K, Hu C, Huang Y, Wei L, Zhang Y, Ji J, Chen Y, Liu H. Sun S, et al. Among authors: pan y. Sci Transl Med. 2025 Mar 5;17(788):eado0020. doi: 10.1126/scitranslmed.ado0020. Epub 2025 Mar 5. Sci Transl Med. 2025. PMID: 40043140
Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study.
Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, Wang Z, Shu Y, Shi J, Hu Y, Wang Q, Cheng Y, Wu F, Chen J, Lin X, Wang Y, Huang J, Cui J, Cao L, Liu Y, Zhang Y, Pan Y, Zhao J, Wang L, Chang J, Chen Q, Ren X, Zhang W, Fan Y, He Z, Fang J, Gu K, Dong X, Jin F, Gao H, An G, Ding C, Jiang X, Xiong J, Zhou X, Hu S, Lu P, Liu A, Guo S, Huang J, Zhu C, Zhao J, Gao B, Chen Y, Hu C, Zhang J, Zhang H, Zhao H, Wang Z, Ma X, Shi W. Zhou C, et al. Among authors: pan y. J Immunother Cancer. 2024 Nov 27;12(11):e009240. doi: 10.1136/jitc-2024-009240. J Immunother Cancer. 2024. PMID: 39608979 Free PMC article. Clinical Trial.
21,126 results
You have reached the last available page of results. Please see the User Guide for more information.